PURPOSE: Current development of targeted agents for the treatment of colorectal cancer include the clinical evaluation of kinase inhibitors, such as enzastaurin, a serine/threonine kinase inhibitor designed to suppress signaling through Protein Kinase C (PKC) and AKT pathways. Little is known about the expression of PKC-beta in colorectal cancer or the prognostic value in colorectal cancer, which was the focus of the present study. METHODS: PKC-beta II protein expression was examined in 99 primary colorectal adenocarcinomas and 33 corresponding regional lymph node metastases by immunohistochemistry (IHC). The PKC-beta II immunoreactivity was mutually compared and correlated with survival information of all examined patients. RESULTS: Immunohistochemical expression of PKC-beta II was detected in 18/99 carcinomas (18.2%). There was no correlation between PKC-beta II staining and traditional clinicopathological parameters. However the median survival was 2.2 years in PKC-beta II expressing tumors compared to 5.4 in PKC-beta II negative tumors (p = 0.25), with a trend for association to poor prognosis. CONCLUSION: We here describe for the first time the immunohistochemical detection of PKC-beta II in patients with colorectal cancer and show a trend associating with poor survival. The role of PKC-beta II staining in colorectal tumors deserves further evaluation.
PURPOSE: Current development of targeted agents for the treatment of colorectal cancer include the clinical evaluation of kinase inhibitors, such as enzastaurin, a serine/threonine kinase inhibitor designed to suppress signaling through Protein Kinase C (PKC) and AKT pathways. Little is known about the expression of PKC-beta in colorectal cancer or the prognostic value in colorectal cancer, which was the focus of the present study. METHODS:PKC-beta II protein expression was examined in 99 primary colorectal adenocarcinomas and 33 corresponding regional lymph node metastases by immunohistochemistry (IHC). The PKC-beta II immunoreactivity was mutually compared and correlated with survival information of all examined patients. RESULTS: Immunohistochemical expression of PKC-beta II was detected in 18/99 carcinomas (18.2%). There was no correlation between PKC-beta II staining and traditional clinicopathological parameters. However the median survival was 2.2 years in PKC-beta II expressing tumors compared to 5.4 in PKC-beta II negative tumors (p = 0.25), with a trend for association to poor prognosis. CONCLUSION: We here describe for the first time the immunohistochemical detection of PKC-beta II in patients with colorectal cancer and show a trend associating with poor survival. The role of PKC-beta II staining in colorectal tumors deserves further evaluation.
Authors: Wangsheng Yu; Nicole R Murray; Capella Weems; Lu Chen; Huiping Guo; Richard Ethridge; Jeffrey D Ceci; B Mark Evers; E Aubrey Thompson; Alan P Fields Journal: J Biol Chem Date: 2002-12-11 Impact factor: 5.157
Authors: Jeremy R Graff; Ann M McNulty; Kimberly Ross Hanna; Bruce W Konicek; Rebecca L Lynch; Spring N Bailey; Crystal Banks; Andrew Capen; Robin Goode; Jason E Lewis; Lillian Sams; Karen L Huss; Robert M Campbell; Philip W Iversen; Blake Lee Neubauer; Thomas J Brown; Luna Musib; Sandaruwan Geeganage; Donald Thornton Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Jeewon Kim; Yoon-La Choi; Alice Vallentin; Ben S Hunrichs; Marc K Hellerstein; Donna M Peehl; Daria Mochly-Rosen Journal: Cancer Res Date: 2008-08-15 Impact factor: 12.701